Compounded GLP-1s in 2026: what's still legal, what changed, and what it costs

How we got here

In 2022, the FDA declared a shortage of semaglutide. Under federal law, a declared shortage allows licensed compounding pharmacies to produce copies of FDA-approved drugs. Thousands of 503A and 503B pharmacies took advantage of this — legally — and built a billion-dollar market for compounded GLP-1s at a fraction of the branded price. At its peak, 24% of Americans who had ever taken a GLP-1 were using a compounded version.

The pharmaceutical companies whose drugs were being undercut were not pleased. Novo Nordisk and Eli Lilly filed more than 130 lawsuits across 40 states. Novo secured 44 permanent injunctions. Eli Lilly sued the two largest compounders — Empower Pharmacy and Strive Pharmacy — over compounded tirzepatide.

On February 21, 2025, the FDA resolved the semaglutide shortage. The shortage exemption expired. On September 9, 2025 — the same day President Trump issued a memorandum on prescription drug advertising — the FDA sent 40 warning letters and 100 cease-and-desist notices to compounders and telehealth companies in a single day. The single largest enforcement action in the history of compounding pharmacy regulation.

The price war nobody expected

Here is what changed that nobody anticipated: instead of simply suing the compounders out of existence, Big Pharma also dropped their prices. Aggressively.

When compounded semaglutide was $199 and Wegovy was $1,349, the value proposition for compounders was overwhelming. At $249 with full FDA approval, manufacturing standards, and Novo's quality controls behind it, the math changed. The compounders forced a permanent price reduction in the branded market — whether they survive or not, that outcome is already locked in.

What compounders can still legally make

The legal landscape is more nuanced than the headlines suggest. The FDA's enforcement targets products that are "essentially a copy" of the branded drug. Compounded formulations with meaningful modifications remain permissible.

The most common workaround: adding B vitamins. As of late 2025, approximately 80% of compounded GLP-1 prescriptions included supplemental ingredients — primarily B6 or B12 — which changes the formulation enough to avoid the "essentially a copy" classification under current FDA interpretation. This is not a loophole; it is a documented clinical practice, as B vitamins can help manage nausea during GLP-1 therapy. But it is also, plainly, a regulatory strategy.

The legitimate compounding infrastructure has not collapsed. Empower Pharmacy in Houston operates a 382,000-square-foot facility serving 33,000 prescribers. Strive Pharmacy in Arizona is breaking ground on a 350,000-square-foot headquarters and filed an antitrust countersuit against Eli Lilly and Novo Nordisk simultaneously in January 2026, arguing coordinated exclusionary conduct. These are not garage operations — and they intend to be here in 20 years.

The grey market is a different story

While the compounding vs. Big Pharma fight plays out in court, the federal government has been running a quieter and more effective campaign against the grey market — unregulated vendors selling peptides labeled "for research use only" with no prescription, no physician oversight, and no quality guarantee.

In December 2025, U.S. Customs officers in Cincinnati seized more than 5,000 packages of unapproved peptide products from a single shipping container — the largest single peptide seizure in U.S. history. It barely made the news.

The attrition among major grey market vendors has been significant:

The safety data on grey market products is not abstract. Independent testing has found impurity rates as high as 86% in worst-case samples from unregulated suppliers. Hospitalization odds were 2.35 times higher for compounded GLP-1 products versus branded versions — a gap that likely reflects both legitimate compounders and grey market products together in the adverse event data, but is a signal worth taking seriously. Imports of peptide compounds from China hit $328 million in the first nine months of 2025, double the prior year — much of it bound for grey market vendors. Sixty percent of Chinese manufacturers exporting "semaglutide" are not permitted to distribute it in China for human use.

The grey market's collapse is not a loss for people who care about their health. It is a correction. The vendors that built businesses on unverified quality, opaque sourcing, and no physician oversight are the right ones to lose.

The 503B permanent exclusion: what the April 2026 proposal adds

On April 30, 2026, the FDA proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The comment period closes June 29, 2026. If finalized, the rule would prohibit 503B outsourcing facilities from compounding these drugs from bulk even if a future shortage were declared. The practical effect on 503B is zero — those facilities are already shut out since the shortage ended. The legal effect is a permanent door-close rather than a conditional one. For a deep look at the tirzepatide-specific legal question, see is compounded tirzepatide still legal in 2026.

The regulatory outlook: RFK, tariffs, and what's still in flux

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced on the Joe Rogan Experience that 14 of the 19 peptides the previous administration had classified as potentially unsafe would be reclassified — making BPC-157, TB-500, Thymosin Alpha-1, CJC-1295, Ipamorelin, Selank, Semax, and others available again through licensed compounding pharmacies.

As of early April 2026, that reclassification has not been formally published in the Federal Register. Kennedy announced it on a podcast. Until the rule appears in the Federal Register, it is a policy statement, not enforceable law. The compounding industry is in limbo on these compounds. Worth watching closely.

On April 2, 2026, President Trump signed an executive order imposing a 100% tariff on imported patented pharmaceuticals and their active ingredients. Companies committing to manufacture in the U.S. get 20%. Companies that signed pricing and onshoring agreements — including Eli Lilly and Novo Nordisk — get 0% through January 2029. Generic pharmaceuticals are exempt, reassessed in one year.

The implication for compounders: approximately 85% of active pharmaceutical ingredients consumed in the U.S. are imported, primarily from China and India. Compounders sourcing bulk APIs from overseas are recalculating margins in real time. The tariff structure rewards domestic manufacturing — companies like Empower and Strive that are already investing in U.S.-based facilities are positioned on the right side of this.

A case study in why provider selection matters

Not all telehealth providers are operating the same way. The market's rapid growth attracted some companies whose operational infrastructure did not keep pace with their marketing.

Hone Health is instructive. They report $113.5 million in annual recurring revenue, 82% year-over-year growth, 300,000 patients tested, and a 4.8-star rating on Trustpilot from over 10,000 reviews. Those numbers look strong.

They also have 113 complaints on the Better Business Bureau — 71 of them filed in the last twelve months alone. The complaints describe a customer charged $1,341 over nine months without receiving a product or service. Multiple customers billed after cancellation. Customer support that is entirely an AI chatbot — not AI-assisted, a chatbot — that, according to complainants, denied that payments existed even when customers provided bank statements. A hidden $45 blood draw not disclosed during sign-up.

The Trustpilot rating measures marketing. The BBB complaints measure operations. Both numbers are real. Only one of them tells you what happens when something goes wrong.

Hone is not unique in this pattern. The telehealth GLP-1 space grew fast enough that some companies scaled their customer acquisition before scaling their support and quality controls. The due diligence questions below are designed to surface the difference before you commit.

The bottom line

The peptide market is not imploding. It is correcting. The grey market vendors who built businesses on untested, impurity-laden compounds are being shut down or prosecuted. The legitimate compounders are consolidating and fighting for their market position in court. Big Pharma has been forced to compete on price for the first time, permanently changing what access costs. And the regulatory direction — regardless of the chaos around implementation — is toward more legitimate access through physician-supervised channels, not less.

For people looking to access GLP-1 programs: branded options are now meaningfully cheaper than they were twelve months ago. Compounded options with physician oversight and licensed pharmacy sourcing remain available. The grey market option carries real quality risk and increasing legal exposure. The decision is clearer than it has ever been.